{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:02:55Z","timestamp":1785855775887,"version":"3.56.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,2,10]],"date-time":"2016-02-10T00:00:00Z","timestamp":1455062400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KUN2010-4722"],"award-info":[{"award-number":["KUN2010-4722"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KUN2009-4402"],"award-info":[{"award-number":["KUN2009-4402"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"name":"nijmeegs offensief tegen kanker"},{"DOI":"10.13039\/501100006209","name":"Radboud Universitair Medisch Centrum","doi-asserted-by":"publisher","award":["AGIKO"],"award-info":[{"award-number":["AGIKO"]}],"id":[{"id":"10.13039\/501100006209","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Netherlands Organization for Scientific Research","award":["95100106"],"award-info":[{"award-number":["95100106"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s00262-016-1796-7","type":"journal-article","created":{"date-parts":[[2016,2,10]],"date-time":"2016-02-10T17:37:15Z","timestamp":1455125835000},"page":"327-339","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity"],"prefix":"10.1007","volume":"65","author":[{"given":"Kalijn F.","family":"Bol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik H. J. G.","family":"Aarntzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette M.","family":"Pots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel A. M.","family":"Olde Nordkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy W. M. M.","family":"van de Rakt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"Scharenborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemiek J.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom G. M.","family":"van Oorschot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra A. J.","family":"Croockewit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willeke A. M.","family":"Blokx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim J. G.","family":"Oyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto C.","family":"Boerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roel D. M.","family":"Mus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"van Rossum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal A. A.","family":"van der Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis J. A.","family":"Punt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gosse J.","family":"Adema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl G.","family":"Figdor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. Jolanda M.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerty","family":"Schreibelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,10]]},"reference":[{"key":"1796_CR1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/32588","volume":"392","author":"J Banchereau","year":"1998","unstructured":"Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245\u2013252","journal-title":"Nature"},{"key":"1796_CR2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nm1039","volume":"10","author":"CG Figdor","year":"2004","unstructured":"Figdor CG, de Vries IJM, Lesterhuis WJ, Melief CJM (2004) Dendritic cell immunotherapy: mapping the way. Nat Med 10:475\u2013480","journal-title":"Nat Med"},{"key":"1796_CR3","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.critrevonc.2007.12.007","volume":"66","author":"WJ Lesterhuis","year":"2008","unstructured":"Lesterhuis WJ, Aarntzen EHJG, Vries IJM et al (2008) Dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol 66:118\u2013134","journal-title":"Crit Rev Oncol Hematol"},{"key":"1796_CR4","first-page":"5091","volume":"9","author":"IJM Vries de","year":"2003","unstructured":"de Vries IJM, Lesterhuis WJ, Scharenborg NM et al (2003) Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 9:5091\u20135100","journal-title":"Clin Cancer Res"},{"key":"1796_CR5","first-page":"12","volume":"63","author":"IJM Vries de","year":"2003","unstructured":"de Vries IJM, Krooshoop DJEB, Scharenborg NM et al (2003) Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 63:12\u201317","journal-title":"Cancer Res"},{"key":"1796_CR6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ijc.1323","volume":"93","author":"H Jonuleit","year":"2001","unstructured":"Jonuleit H, Giesecke-Tuettenberg A, Tuting T et al (2001) A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 93:243\u2013251","journal-title":"Int J Cancer"},{"key":"1796_CR7","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1200\/JCO.2010.30.7744","volume":"29","author":"H Okada","year":"2011","unstructured":"Okada H, Kalinski P, Ueda R et al (2011) Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 29:330\u2013336","journal-title":"J Clin Oncol"},{"key":"1796_CR8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/ni1162","volume":"6","author":"R Sporri","year":"2005","unstructured":"Sporri R, Sousa CRE (2005) Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4(+) T cell populations lacking helper function. Nat Immunol 6:163\u2013170","journal-title":"Nat Immunol"},{"key":"1796_CR9","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nri1391","volume":"4","author":"S Akira","year":"2004","unstructured":"Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4:499\u2013511","journal-title":"Nat Rev Immunol"},{"key":"1796_CR10","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/ni1112","volume":"5","author":"A Iwasaki","year":"2004","unstructured":"Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5:987\u2013995","journal-title":"Nat Immunol"},{"key":"1796_CR11","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1182\/blood-2009-11-251884","volume":"116","author":"G Schreibelt","year":"2010","unstructured":"Schreibelt G, Benitez-Ribas D, Schuurhuis D et al (2010) Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood 116:564\u2013574","journal-title":"Blood"},{"key":"1796_CR12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jim.2005.01.005","volume":"298","author":"TG Berger","year":"2005","unstructured":"Berger TG, Strasser E, Smith R et al (2005) Efficient elutriation of monocytes within a closed system (Elutra (TM)) for clinical-scale generation of dendritic cells. J Immunol Methods 298:61\u201372","journal-title":"J Immunol Methods"},{"key":"1796_CR13","doi-asserted-by":"crossref","first-page":"5460","DOI":"10.1158\/1078-0432.CCR-11-3368","volume":"18","author":"EH Aarntzen","year":"2012","unstructured":"Aarntzen EH, Schreibelt G, Bol K et al (2012) Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin Cancer Res 18:5460\u20135470","journal-title":"Clin Cancer Res"},{"key":"1796_CR14","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/nbt1154","volume":"23","author":"IJM Vries de","year":"2005","unstructured":"de Vries IJM, Lesterhuis WJ, Barentsz JO et al (2005) Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 23:1407\u20131413","journal-title":"Nat Biotechnol"},{"key":"1796_CR15","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00262-012-1263-z","volume":"61","author":"EH Aarntzen","year":"2012","unstructured":"Aarntzen EH, De Vries IJ, Goertz JH et al (2012) Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters. Cancer Immunol Immunother 61:2003\u20132011","journal-title":"Cancer Immunol Immunother"},{"key":"1796_CR16","doi-asserted-by":"crossref","first-page":"6102","DOI":"10.1158\/0008-5472.CAN-12-2479","volume":"72","author":"EH Aarntzen","year":"2012","unstructured":"Aarntzen EH, Bol K, Schreibelt G et al (2012) Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma. Cancer Res 72:6102\u20136110","journal-title":"Cancer Res"},{"key":"1796_CR17","doi-asserted-by":"crossref","first-page":"5779","DOI":"10.1200\/JCO.2005.06.478","volume":"23","author":"IJM Vries de","year":"2005","unstructured":"de Vries IJM, Bernsen MR, Lesterhuis WJ et al (2005) Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 23:5779\u20135787","journal-title":"J Clin Oncol"},{"key":"1796_CR18","doi-asserted-by":"crossref","first-page":"e1019197","DOI":"10.1080\/2162402X.2015.1019197","volume":"4","author":"KF Bol","year":"2015","unstructured":"Bol KF, Figdor CG, Aarntzen EHJG et al (2015) Intranodal vaccination with mRNA-optimised dendritic cells in metastatic melanoma patients. Oncoimmunology 4:e1019197","journal-title":"Oncoimmunology"},{"key":"1796_CR19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jim.2011.12.010","volume":"377","author":"AM Nuffel Van","year":"2012","unstructured":"Van Nuffel AM, Tuyaerts S, Benteyn D et al (2012) Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens. J Immunol Methods 377:23\u201336","journal-title":"J Immunol Methods"},{"key":"1796_CR20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00262-008-0506-5","volume":"58","author":"JF Jacobs","year":"2009","unstructured":"Jacobs JF, Aarntzen EH, Sibelt LA et al (2009) Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients. Cancer Immunol Immunother 58:145\u2013151","journal-title":"Cancer Immunol Immunother"},{"key":"1796_CR21","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","volume":"33","author":"HE Teulings","year":"2015","unstructured":"Teulings HE, Limpens J, Jansen SN et al (2015) Vitiligo-like depigmentation in patients with stage III\u2013IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol 33:773\u2013781","journal-title":"J Clin Oncol"},{"key":"1796_CR22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1158\/0008-5472.CAN-12-1127","volume":"73","author":"EH Aarntzen","year":"2013","unstructured":"Aarntzen EH, de Vries I, Lesterhuis WJ et al (2013) Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res 73:19\u201329","journal-title":"Cancer Res"},{"key":"1796_CR23","first-page":"5091","volume":"30","author":"WJ Lesterhuis","year":"2010","unstructured":"Lesterhuis WJ, de Vries I, Schreibelt G et al (2010) Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Anticancer Res 30:5091\u20135097","journal-title":"Anticancer Res"},{"key":"1796_CR24","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/CJI.0b013e31821dcb31","volume":"34","author":"S Wilgenhof","year":"2011","unstructured":"Wilgenhof S, Van Nuffel AM, Corthals J et al (2011) Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother 34:448\u2013456","journal-title":"J Immunother"},{"key":"1796_CR25","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nm0398-328","volume":"4","author":"FO Nestle","year":"1998","unstructured":"Nestle FO, Alijagic S, Gilliet M et al (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328\u2013332","journal-title":"Nat Med"},{"key":"1796_CR26","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00262-010-0942-x","volume":"60","author":"WJ Lesterhuis","year":"2011","unstructured":"Lesterhuis WJ, Schreibelt G, Scharenborg NM et al (2011) Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Cancer Immunol Immunother 60:249\u2013260","journal-title":"Cancer Immunol Immunother"},{"key":"1796_CR27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000471561","volume":"16","author":"A Steg","year":"1989","unstructured":"Steg A, Leleu C, Debre B, Boccon-Gibod L, Sicard D (1989) Systemic bacillus Calmette-Guerin infection, \u2018BCGitis\u2019, in patients treated by intravesical bacillus Calmette-Guerin therapy for bladder cancer. Eur Urol 16:161\u2013164","journal-title":"Eur Urol"},{"key":"1796_CR28","doi-asserted-by":"crossref","first-page":"e113472","DOI":"10.1371\/journal.pone.0113472","volume":"9","author":"S Al-Hajoj","year":"2014","unstructured":"Al-Hajoj S, Memish Z, Abuljadayel N, AlHakeem R, AlRabiah F, Varghese B (2014) Molecular confirmation of Bacillus Calmette Guerin vaccine related adverse events among Saudi Arabian children. PLoS ONE 9:e113472","journal-title":"PLoS ONE"},{"key":"1796_CR29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(98)07186-4","volume":"353","author":"JB Vermorken","year":"1999","unstructured":"Vermorken JB, Claessen AM, van Tinteren H et al (1999) Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353:345\u2013350","journal-title":"Lancet"},{"key":"1796_CR30","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-12-1879","volume":"19","author":"EH Aarntzen","year":"2013","unstructured":"Aarntzen EH, Srinivas M, Bonetto F et al (2013) Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells. Clin Cancer Res 19:1525\u20131533","journal-title":"Clin Cancer Res"},{"key":"1796_CR31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4049\/jimmunol.1101029","volume":"188","author":"P Kalinski","year":"2012","unstructured":"Kalinski P (2012) Regulation of immune responses by prostaglandin E2. J Immunol 188:21\u201328","journal-title":"J Immunol"},{"key":"1796_CR32","author":"K Bol","year":"2015","unstructured":"Bol K, Aarntzen EHJG, Hout FEM et al (2015) Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. Oncoimmunology. doi: 10.1080\/2162402X.2015.1057673","journal-title":"Oncoimmunology"},{"key":"1796_CR33","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1158\/1078-0432.CCR-07-0892","volume":"13","author":"TF Gajewski","year":"2007","unstructured":"Gajewski TF (2007) Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 13:5256\u20135261","journal-title":"Clin Cancer Res"},{"key":"1796_CR34","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/annonc\/mdj138","volume":"17","author":"D Schadendorf","year":"2006","unstructured":"Schadendorf D, Ugurel S, Schuler-Thurner B et al (2006) Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17:563\u2013570","journal-title":"Ann Oncol"},{"key":"1796_CR35","doi-asserted-by":"crossref","first-page":"5725","DOI":"10.1158\/1078-0432.CCR-11-1261","volume":"17","author":"WJ Lesterhuis","year":"2011","unstructured":"Lesterhuis WJ, de Vries I, Schreibelt G et al (2011) Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res 17:5725\u20135735","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-016-1796-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-016-1796-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-016-1796-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T08:21:34Z","timestamp":1567585294000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-016-1796-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,10]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["1796"],"URL":"https:\/\/doi.org\/10.1007\/s00262-016-1796-7","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.730481855.793559567","asserted-by":"object"}]},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,10]]}}}